Foreword |
|
ix | |
Preface (First Edition) |
|
xi | |
Preface (Second Edition) |
|
xiii | |
Abbreviations |
|
xiv | |
Key to symbols |
|
xvii | |
|
Chapter 1 An overview of the immune system: innate and adaptive immunity and the inflammatory response |
|
|
1 | (14) |
|
|
1 | (1) |
|
|
1 | (2) |
|
The immune system: an overview |
|
|
3 | (9) |
|
The evolution of the immune system |
|
|
12 | (2) |
|
|
14 | (1) |
|
Chapter 2 Antigens and antibodies |
|
|
15 | (12) |
|
|
15 | (1) |
|
|
15 | (3) |
|
|
18 | (1) |
|
|
19 | (6) |
|
Antigen-antibody interaction |
|
|
25 | (1) |
|
|
26 | (1) |
|
Chapter 3 The complement system |
|
|
27 | (12) |
|
|
27 | (1) |
|
The classical and lectin pathways |
|
|
28 | (2) |
|
|
30 | (2) |
|
|
32 | (1) |
|
Biological consequences of complement activation |
|
|
32 | (4) |
|
Tests of complement function |
|
|
36 | (1) |
|
|
37 | (2) |
|
Chapter 4 Serological testing |
|
|
39 | (12) |
|
|
39 | (1) |
|
|
40 | (10) |
|
|
50 | (1) |
|
Chapter 5 Cells and tissues of the immune system |
|
|
51 | (20) |
|
|
51 | (1) |
|
|
51 | (3) |
|
Secondary lymphoid tissue |
|
|
54 | (4) |
|
|
58 | (2) |
|
Distinguishing between immune cells |
|
|
60 | (4) |
|
|
64 | (5) |
|
Mucosal lymphocyte recirculation |
|
|
69 | (1) |
|
|
70 | (1) |
|
Chapter 6 The major histocompatibility complex |
|
|
71 | (10) |
|
|
71 | (1) |
|
|
71 | (2) |
|
Major histocompatibility antigens |
|
|
73 | (1) |
|
The major histocompatibility complex |
|
|
73 | (2) |
|
|
75 | (1) |
|
MHC--disease associations |
|
|
76 | (2) |
|
Other applications of tissue typing |
|
|
78 | (1) |
|
|
79 | (2) |
|
Chapter 7 Antigen presentation and cytokines |
|
|
81 | (14) |
|
|
81 | (1) |
|
|
81 | (3) |
|
|
84 | (3) |
|
Antigen processing and presentation |
|
|
87 | (2) |
|
Antigen presenting by CD1 molecules |
|
|
89 | (1) |
|
Antigen presentation by B cells and non-professional antigen presenting cells |
|
|
90 | (1) |
|
|
91 | (3) |
|
|
94 | (1) |
|
Chapter 8 The biology of T lymphocytes |
|
|
95 | (18) |
|
|
95 | (1) |
|
|
95 | (3) |
|
T-cell development and maturation |
|
|
98 | (2) |
|
|
100 | (2) |
|
The role of CD4+ T lymphocytes |
|
|
102 | (3) |
|
|
105 | (4) |
|
|
109 | (1) |
|
|
109 | (1) |
|
|
110 | (1) |
|
|
111 | (2) |
|
Chapter 9 The biology of B lymphocytes |
|
|
113 | (12) |
|
|
113 | (1) |
|
Antigen recognition by B cells |
|
|
113 | (1) |
|
Development and maturation of B lymphocytes |
|
|
114 | (1) |
|
Activation of the B lymphocyte |
|
|
115 | (2) |
|
B-cell receptor diversity |
|
|
117 | (2) |
|
The immunoglobulin class switch |
|
|
119 | (1) |
|
|
120 | (1) |
|
Kinetics of the humoral immune response |
|
|
120 | (1) |
|
|
120 | (1) |
|
|
120 | (1) |
|
|
121 | (3) |
|
|
124 | (1) |
|
Chapter 10 Testing of cellular immune function |
|
|
125 | (6) |
|
|
125 | (1) |
|
Lymphocyte stimulation tests |
|
|
125 | (3) |
|
Tests of cytotoxic function |
|
|
128 | (1) |
|
Tests of phagocytic cell function |
|
|
128 | (2) |
|
|
130 | (1) |
|
Chapter 11 Immune suppression |
|
|
131 | (8) |
|
|
131 | (1) |
|
|
131 | (1) |
|
Antibody-mediated suppression |
|
|
132 | (1) |
|
Immunoregulatory macrophages |
|
|
133 | (1) |
|
The neuroendocrine--immunological loop |
|
|
133 | (1) |
|
Regulatory (suppressor) T lymphocytes |
|
|
134 | (4) |
|
|
138 | (1) |
|
Chapter 12 Hypersensitivity mechanisms |
|
|
139 | (14) |
|
|
139 | (1) |
|
The Gell and Coombs classification of hypersensitivity |
|
|
140 | (1) |
|
|
140 | (3) |
|
|
143 | (2) |
|
'type III hypersensitivity |
|
|
145 | (3) |
|
|
148 | (4) |
|
|
152 | (1) |
|
Chapter 13 The immune response to infectious agents |
|
|
153 | (14) |
|
|
153 | (1) |
|
The immune response to viral infection |
|
|
153 | (3) |
|
The immune response to bacterial infection |
|
|
156 | (3) |
|
The immune response to helminth infection |
|
|
159 | (2) |
|
The immune response to protozoal infection |
|
|
161 | (2) |
|
The immune response to fungal infection |
|
|
163 | (2) |
|
|
165 | (2) |
|
Chapter 14 Cancer immunology and immune system neoplasia |
|
|
167 | (14) |
|
|
167 | (1) |
|
|
167 | (1) |
|
The antitumour immune response |
|
|
168 | (1) |
|
Tumour-promoting immune activity |
|
|
169 | (1) |
|
Immunotherapy to enhance the antitumour immune response |
|
|
170 | (1) |
|
Tumours of the immune system |
|
|
171 | (8) |
|
|
179 | (2) |
|
Chapter 15 Immunological tolerance |
|
|
181 | (6) |
|
|
181 | (1) |
|
|
181 | (1) |
|
|
182 | (1) |
|
|
182 | (1) |
|
Oral tolerance as immunotherapy |
|
|
183 | (1) |
|
|
184 | (1) |
|
|
185 | (1) |
|
|
186 | (1) |
|
Chapter 16 Autoimmunity and autoimmune disease |
|
|
187 | (14) |
|
|
187 | (1) |
|
|
188 | (1) |
|
The genetic basis for autoimmunity |
|
|
189 | (1) |
|
Age susceptibility to autoimmune disease |
|
|
190 | (1) |
|
Hormonal influence on autoimmunity |
|
|
190 | (1) |
|
Primary versus secondary autoimmune disease |
|
|
190 | (6) |
|
Immunodiagnostic tests for autoimmunity |
|
|
196 | (3) |
|
|
199 | (2) |
|
|
201 | (12) |
|
|
201 | (1) |
|
Factors predisposing to allergic disease |
|
|
202 | (2) |
|
|
204 | (1) |
|
Allergic disease in animals |
|
|
205 | (5) |
|
Diagnosis of allergic disease |
|
|
210 | (2) |
|
|
212 | (1) |
|
Chapter 18 Immune system ontogeny and neonatal immunology |
|
|
213 | (8) |
|
|
213 | (1) |
|
|
213 | (1) |
|
Passive transfer of maternal immune protection |
|
|
213 | (2) |
|
|
215 | (2) |
|
Failure of passive transfer |
|
|
217 | (1) |
|
|
218 | (1) |
|
|
218 | (1) |
|
Early life immune development |
|
|
219 | (1) |
|
|
220 | (1) |
|
Chapter 19 Immunodeficiency |
|
|
221 | (12) |
|
|
221 | (1) |
|
|
221 | (7) |
|
Secondary immunodeficiency |
|
|
228 | (3) |
|
|
231 | (2) |
|
|
233 | (16) |
|
|
233 | (1) |
|
|
233 | (1) |
|
|
234 | (1) |
|
|
235 | (2) |
|
|
237 | (2) |
|
Vaccines other than for infectious disease |
|
|
239 | (1) |
|
|
239 | (1) |
|
|
240 | (1) |
|
Future vaccine developments |
|
|
240 | (1) |
|
Basic principles of vaccination |
|
|
240 | (4) |
|
|
244 | (1) |
|
Adverse consequences of vaccination |
|
|
244 | (3) |
|
|
247 | (2) |
|
|
249 | (16) |
|
|
249 | (1) |
|
|
250 | (5) |
|
|
255 | (1) |
|
|
255 | (1) |
|
Allergen-specific immunotherapy |
|
|
256 | (1) |
|
Intravenous immunoglobulin therapy |
|
|
257 | (1) |
|
Recombinant cytokine therapy |
|
|
258 | (1) |
|
|
258 | (1) |
|
Monoclonal antibody therapy |
|
|
259 | (1) |
|
Antigen-specific immunotherapy |
|
|
259 | (1) |
|
|
260 | (1) |
|
|
260 | (2) |
|
|
262 | (1) |
|
|
262 | (1) |
|
|
263 | (2) |
|
Chapter 22 Case studies in clinical immunology |
|
|
265 | (30) |
|
|
265 | (1) |
|
The basis of immune-mediated disease |
|
|
265 | (1) |
|
How common is immune-mediated disease? |
|
|
266 | (1) |
|
|
266 | (1) |
|
Case 1 Canine immune-mediated haemolytic anaemia |
|
|
267 | (2) |
|
Case 2 Canine immune-mediated thrombocytopenia |
|
|
269 | (2) |
|
Case 3 Canine systemic lupus erythematosus |
|
|
271 | (3) |
|
Case 4 Feline blood transfusion |
|
|
274 | (2) |
|
Case 5 Feline multiple myeloma |
|
|
276 | (2) |
|
Case 6 Equine purpura haemorrhagica |
|
|
278 | (1) |
|
Case 7 Bovine thymic lymphoma |
|
|
279 | (1) |
|
Case 8 Canine atopic dermatitis |
|
|
280 | (1) |
|
Case 9 Equine severe combined immunodeficiency |
|
|
281 | (1) |
|
Case 10 Canine lymphocytic thyroiditis |
|
|
282 | (2) |
|
Case 11 Canine immune-mediated polyarthritis |
|
|
284 | (2) |
|
Case 12 Bovine allergic rhinitis |
|
|
286 | (1) |
|
Case 13 Canine drug reaction |
|
|
287 | (2) |
|
Case 14 Canine trapped neutrophil syndrome |
|
|
289 | (1) |
|
Case 15 Feline lymphoid leukaemia |
|
|
290 | (2) |
|
Case 16 Equine neonatal isoerythrolysis |
|
|
292 | (1) |
|
Case 17 Immunological aspects of a herd outbreak of bovine viral diarrhoea virus infection |
|
|
293 | (2) |
Glossary |
|
295 | (14) |
Index |
|
309 | |